MedTrace Logo

Safety Study of GCS-100 to Treat Chronic Kidney Disease

NCT01717248 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2013-06-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of GCS-100 as a treatment for chronic kidney disease.

Conditions

Interventions

DRUG

GCS-100

GCS-100 is a modified citrus pectin that binds to and sequesteres circulating galectin-3, a protein that has been shown to promote organ disease (fibrosis).

Sponsors & Collaborators

  • La Jolla Pharmaceutical Company

    lead INDUSTRY

Principal Investigators

  • Pablo Pergola, MD · Renal Associaties PA, Research Division

  • Geoffrey Block, MD · Denver Nephrologists, PC

  • Bhupinder Singh, MD · Southwest Clinical Research Institute, LLC

  • George Fadda, MD · California Institute of Renal Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01717248 on ClinicalTrials.gov